Copyright © 2000 by the European Society of Cardiology.
The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae -specific IgG antibodies
a Departments of Clinical Chemistry, Umeå University, Sweden
b Virology, Umeå University, Sweden
d Public Health and Clinical Medicine, Umeå University, Sweden
c The National Public Health Institute, Oulu, Finland
revised June 15, 1999; accepted June 16, 1999
Abstract
Aims To investigate a possible relationship between the atherogenic properties of lipoprotein(a) (Lp(a)) and Chlamydia pneumoniae infections.
Methods and Results The study population was nested within the Västerbotten Intervention Program or the WHO MONICA project. In this incident case-control study, 78 patients who had suffered acute myocardial infarction and 156 matched controls were included. The contents of circulating immune complexes were analysed for C. pneumoniae IgG antibodies and Lp(a). A significantly larger proportion of cases than controls had 
13mg.l–1Lp(a) and a C. pneumoniae specific IgG antibody titre 1/2 in circulating immune complexes (odds ratio=3·8).
Conclusion The proatherogenic effects of Lp(a) may be enhanced and/or partly mediated through the formation of circulating immune complexes containing C. pneumoniae -specific IgG antibodies. The connection between chronic C. pneumoniae infections and atherosclerosis may, at least in part, be explained by an interaction with Lp(a) through the formation of circulating immune complexes.
Key Words: Lipoprotein(a), Chlamydia pneumoniae, circulating immune complex, case-control study, acute myocardial infarction
f1 Correspondence: Christine Ahlbeck Glader, MD, Department of Clinical Chemistry, Ume
University, SE-901 85 Ume, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Parratt, R. Tavendale, J. O'Riordan, D. Parratt, and R. Swingler Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 292 - 299. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Iwamoto, S. Fukuda, S. Shimizu, and M. Takasaki Long-Term Effects of Lipoprotein(a) on Carotid Atherosclerosis in Elderly Japanese J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2004; 59(1): M62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.A Glader, L.S Birgander, S Soderberg, H.P Ildgruben, P Saikku, A Waldenstrom, and G.H Dahlen Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis Eur. Heart J., January 2, 2003; 24(2): 198 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tarnacka, G. Gromadzka, and A. Czlonkowska Increased Circulating Immune Complexes in Acute Stroke: The Triggering Role of Chlamydia pneumoniae and Cytomegalovirus Stroke, April 1, 2002; 33(4): 936 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stollberger and J. Finsterer Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215. [Full Text] [PDF]
|
|
|
|
|
|
J. Danesh, P. Whincup, S. Lewington, M. Walker, L. Lennon, A. Thomson, Y.-K. Wong, X. Zhou, and M. Ward Chlamydia pneumoniae IgA titres and coronary heart disease. Prospective study and meta-analysis Eur. Heart J., March 1, 2002; 23(5): 371 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tavendale, D. Parratt, S.D. Pringle, R. A'brook, and H. Tunstall-Pedoe Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events. The Scottish Heart Health Study Cohort Eur. Heart J., February 2, 2002; 23(4): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boman and M. R. Hammerschlag Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Hoffmeister, D. Rothenbacher, G. Bode, K. Persson, W. Marz, M. A. Nauck, H. Brenner, V. Hombach, and W. Koenig Current Infection With Helicobacter pylori, but Not Seropositivity to Chlamydia pneumoniae or Cytomegalovirus, Is Associated With an Atherogenic, Modified Lipid Profile Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 427 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, Y.-k. Wong, M. Bernardes-Silva, M. Ward, and R. West Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis Commentary: Adjustment for potential confounders may have been taken too far BMJ, July 22, 2000; 321(7255): 208 - 213. [Abstract] [Full Text]
|
|
|
|
|
|
A. Cassone Chlamydia pneumoniae and lipoprotein(a): the right combination for atherosclerosis? Eur. Heart J., April 2, 2000; 21(8): 599 - 600. [PDF]
|
|